ALB and metabolic dysfunction-associated steatotic liver disease: Unlike chronic kidney disease, where serum creatinine, urinary albumin-to-creatinine ratio and estimated glomerular filtration rate could be used to identify and as biomarkers for therapeutic efficacy, such biomarkers for NAFLD are less known.